Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3

Table 1 Characteristics of the study population n (%)

Characteristic	Patients
	(n = 107)
Age, yr (mean ± SD)1	47.5 (± 8.8)
Gender
Male	68.2 (73)
Female	31.8 (34)
INFL3 polymorphism2
CT	56.2 (36)
CC	28.1 (18)
TT	15.7 (10)
Pre treatment HCV-RNA3
< 600000 UI/mL	44.7 (46)
≥ 6000000 UI/mL	55.3 (57)
Pre treatment elevated ALT4	88.5 (92)
Fibrosis5
Mild to moderate6	59.8 (61)
Advanced7	40.2 (41)
Steatosis	47.6 (51)
BMI (kg/m2) > 27	54.2 (58)
Diabetes	5.6 (6)
Type of peginterferon
alfa 2a	75.7 (81)
alfa 2b	24.3 (26)
RBV dose
Fix8	63.6 (68)
Weight-Based9	36.4 (39)
80/80/80 adherence10	94.4 (101)

¹Available for 105 patients;

²Available for 64 patients;

³Available for 103 patients;

⁴Available for 104 patients;

⁵Available for 102 patients;

⁶Mild to moderate fibrosis includes patients without fibrosis and patients with up to METAVIR F2 fibrosis;

⁷Advanced fibrosis includes patients with METAFIR F3 and cirrhosis;

⁸800 mg/d;

⁹1000 mg/d in patients ≤ 75 kg weight, 1200 mg/d in patients > 75 kg weight;

¹⁰Patients received at least 80% of the peginterferon and RBV doses, and completed at least 80% of the expected treatment duration. ALT: Alanine aminotransferase; HCV: Hepatitis C virus; RBV: Ribavirin; BMI: Body mass index.